🔗 Share this article

An underground economy for unapproved weight-loss drugs is being driven by social media fitness personalities and vendors on messaging platforms, based on new investigations.

Investigational Drug Gaining Traction Online

The experimental drug, which is still in clinical trials, is being advertised by online personalities for its alleged weight-reducing effects. Followers are urged to contact these accounts privately for supplier links, while also receiving discount codes.

Active Trade on Messaging Platforms

Additionally, a robust trade exists on messaging services, where communities with thousands of participants share “before and after” images, administration instructions and claims of rapid UK delivery. Vendors promote the substance there before directing buyers to other platforms for transactions.

Understanding Retatrutide

This medication is an experimental injectable created by US drugmaker Eli Lilly. The treatment targets three intestinal hormones – GLP-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies suggest it could assist patients lose up to a quarter of their body weight. Referred to as the “triple G”, the substance is being promoted digitally as the next Ozempic.

Medical Experts Express Concerns

Nevertheless, doctors and chemists have warned that the distribution of what is still an unapproved medication in the UK is a cause for concern and could lead to users administering substances of unknown origin.

Several professionals stated the popularity for the experimental drug could be linked to the increasing price of licensed weight loss treatments such as Mounjaro.

Legal Position and Implementation

Selling the unapproved drug on social media or messaging apps is illegal in the United Kingdom, as it is an unapproved medication that must not be promoted or supplied for personal consumption under the British medical regulations.

Some influencers try to sidestep the regulations by referring to the substance as a “research chemical” or citing it as “not for human consumption”. The substance is not a restricted drug, but promotion and distribution can still breach pharmaceutical, marketing, and customer regulations, risking penalties, legal action or prison.

Service Response and Material Removal

Based on TikTok, the service has removed problematic material and banned associated hashtags and query recommendations. The organization stated it was committed to maintaining the service safe and allocating resources in enhancing enforcement strategies.

Digital Trading Activities

Investigations also discovered communities with up to nine thousand participants marketing retatrutide using the platform's integrated search feature, which operates like a public directory. Entering “retatrutide” immediately displays channels with thousands of members, populated with images of slimming results, glowing testimonials and step-by-step guides for preparing or administering at residence.

Within moments of entering one group, a vendor posted contact information, where the majority of purchases take place. The seller provided an instruction manual and guaranteed shipping within two days. When asked whether the product was genuine, one seller responded: “You can’t be sure.” Another provided a photo of a supposed laboratory certificate. None asked about body mass, health issues or past usage.

Item Information and Pricing

Within these communities, posts display black plastic parcels with postal service stickers, stating to include fresh supplies. One communication stated: “It took eight of us to load them this morning.”

Buyers can choose between powder vials, prepared at home with sterile water, or ready-to-use pens usually sold at 160 pounds for 20 milligrams. When asked how long a pen should be used, vendors give contradictory responses ranging from a few weeks to “depends on your body”.

Service Oversight and Security Actions

A spokesperson for the messaging service said it actively moderated harmful material on its platform including content that encouraged the “misuse of controlled medications”. The company added that it eliminated “millions of pieces of harmful content each day”.

Healthcare Professional Warnings

“People are injecting materials they can’t verify. Although the research behind retatrutide is valid, these online products may not contain what they claim,” said a pharmacy expert, the director of pharmacy at a pharmacy service.

A medical professional of an online medical service connected the increase in interest to current price rises for authorized slimming medications such as Mounjaro. “With prices increasing, patients are turning to online platforms. But fake injections are extremely risky. You can’t be certain what’s inside or whether the conditions they were made in was clean,” she said.

Her team has previously seen individuals injured by self-injection from unverified sources. “We recognize the frustration, but purchasing from messaging apps or communication platforms is gambling with your health,” said the doctor. “These materials could be contaminated or improperly measured.”

Manufacturer Position

A representative from Eli Lilly stated the substance was in third stage research studies and had not been reviewed or authorized by any regulatory agency anywhere in the world. “Consequently at this point no one can market [it] for human use,” they explained, noting that any product “falsely representing itself as a Lilly experimental substance not yet approved … may expose users to potentially significant health risks”.